Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–60 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluzone® Quadrivalent vaccine Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

NCT01946438
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

NCT04969276
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Glendale, Arizona • San Diego, California • Vista, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

NCT05514002
View directory record Official record
Conditions
Influenza, Human
Interventions
Fluzone Quadrivalent, Flublok Quadrivalent
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 64 Years
Enrollment
3,988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tallahassee, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

NCT02242643
View directory record Official record
Conditions
Influenza
Interventions
FluLaval™ Quadrivalent, Fluzone® Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
2,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02258334
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02563093
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine

NCT02222870
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

NCT02553343
View directory record Official record
Conditions
Influenza
Interventions
High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
792 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Modified mRNA Vaccines in Healthy Adults

NCT05397223
View directory record Official record
Conditions
SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
Interventions
mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
8
States / cities
Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 5, 2026, 7:32 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

NCT03028987
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 49 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 5, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

NCT01946425
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 5, 2026, 7:32 AM EDT